Introduction: Herpes zoster is caused by the reactivation of latent varicella infection within the sensory ganglia, caused by the varicella-zoster virus (VZV). The disease is classically characterized by a painful unilateral vesicular eruption. Complications of the disease include herpes zoster ophthalmicus, Ramsay Hunt syndrome, acute retinal necrosis, and post-herpetic neuralgia. In this paper, we discuss the epidemiology, pathogenesis, clinical features, diagnosis, management, and vaccination strategies of herpes zoster and post-herpetic neuralgia. Method: This paper was developed with input from specialists from Singapore’s public sectors—dermatologists, family physicians, and infectious diseases specialists. Results: The diagnosis of herpes zoster is clinical and can be aided with laboratory investigations. Early initiation of antivirals, within 72 h of onset, can reduce the severity and duration of the condition and decrease the intensity of pain. In patients with a high risk of post-herpetic neuralgia, early initiation of anticonvulsants or tricyclic antidepressants can be considered. Herpes zoster is highly preventable, with the advent of the recombinant zoster vaccine (RZV) providing an overall vaccine efficacy of 97.2%. Procedures such as epidural blocks and subcutaneous or intracutaneous injections of local anesthetics and steroids can be considered for patients with a high risk of post-herpetic neuralgia to reduce its incidence. Conclusion: This article serves as a guideline for clinicians in the diagnosis, investigations, management, and prevention of herpes zoster. With the majority of adults in Singapore currently at risk of developing herpes zoster due to varicella immunization being only introduced in 2020, it is important for clinicians to recognize and manage herpes zoster appropriately.
4 September 2024 in British Journal of Dermatology
Background: A common complication of wounds is the excessive production of fibrotic scar tissue, which can lead to hypertrophic scars or keloids. Currently, no treatments with good evidence for preventing excessive scar tissue formation are available. We explored the use of microneedle patches containing small interfering RNA (siRNA) to inhibit SPARC mRNA in reducing the volume of postoperative scars. Objectives: To compare differences in postoperative scar volume with the daily application of siRNA-embedded dissolving microneedle patches vs. silicone sheets. Methods: This was an 8-week, single-blinded intraindividually controlled randomized trial at a tertiary dermatological centre. Patients with 2-week-old postoperative wounds were included. Each half of the scar was randomly assigned to the microneedle patch or silicone sheet. Three-dimensional (3D) volumes were obtained from the scars via a high-resolution scanner at days 0, 30 and 60. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12622000558729). Results: At day 30, scars treated with microneedle patches had a lower geometric mean volume of 0.79 mm3 vs. scars treated with silicone sheets, with a difference in mean percentage volume reduction of 10.7%. At day 60, scars treated with microneedle patches had a statistically significant lower volume (8.88 mm3) compared with the side treated with silicone sheets (12.77 mm3; P = 0.005), with a difference in mean percentage reduction of 9.7%. Additionally, there was also a statistically significant difference between the percentage reduction in scar volume vs. baseline on the side treated with microneedle patches (mean 83.8%) compared with the side treated with silicone sheets (mean 74.1%). Conclusions: There was a significantly greater reduction in the volume of postoperative scars on the side of the scar treated with microneedle patches compared with the side treated with silicone sheets. This demonstrates the use of transdermal gene-silencing technology in scar inhibition and that siRNA microneedle patches can be effective and safe in reducing scar tissue formation.
14 August 2023 in International Journal of Cosmetic Science
Historically, granulomatous inflammation has been described in association with tertiary syphilis. However, in recent years there have been increasing reports of granulomatous inflammation in patients with secondary syphilis. Here, we discuss two patients who presented with erythematous infiltrated papules and nodules and were eventually diagnosed with granulomatous secondary syphilis, with clearance of their rashes following treatment. We highlight important clues that can point clinicians and histopathologists toward a diagnosis of syphilis instead of differential diagnoses such as leprosy in reaction, cutaneous histiocytosis and lymphoma. Furthermore, after performing a literature review and from our own experiences, we wish to highlight that granulomatous syphilis is often palmoplantar-sparing and its presence may not necessarily be a feature of immunocompromised states, such as HIV infection. In this increasingly connected world, the recognition of an atypical presentation of an age-old disease in patients with different skin types must be underscored by close clinicopathological correlations.
Background: The Comprehensive Quality-of-Life Measure for Acne (CompAQ) is a patient-reported outcome measure (PROM) assessing health-related quality of life (HRQoL) among patients with acne. The measure is one of two acne-specific PROMs that had the strongest evidence to support its use in a recent COSMIN systematic review. Objectives: To build on prior validation studies of CompAQ by confirming several of its known measurement properties in a cohort of patients with acne at three international sites; and, to establish the responsiveness of the measure during acne treatment. Methods: Adults being seen for routine acne treatment at dermatology clinics in Canada, the USA and Singapore were recruited between July 2022 and September 2024 to participate in this cohort study. At each visit, participants completed the CompAQ, which consists of 20 items representing five domains (i.e. emotions, social judgement, social interaction, treatment and symptoms domains) and several other relevant measures. Structural validity was assessed by confirmatory factor analysis, internal consistency by calculating Cronbach’s α values, and construct validity by known groups and convergent validity hypothesis testing. We further evaluated for differential item functioning (DIF) across study site, sex and age. In addition, we assessed responsiveness by change-score validity hypothesis testing and calculating standardized response means (SRMs). Results: Our study included 315 participants [mean (SD) age 25.2 (6.1) years; 219 (69.7%) women] and data were collected from a total of 588 visits. The CompAQ was found to have sufficient structural validity, internal consistency and construct validity among patients at each study site and in the combined cohort. In addition, no statistically significant uniform or nonuniform DIF was flagged for most items when analysing DIF by site, sex and age. Based on SRM estimates, the emotions (SRM 0.927) and symptoms (0.914) domains had the largest responsiveness, while the social judgement (0.606), social interaction (0.522) and treatment (0.787) domains had more moderate responsiveness. Conclusions: CompAQ represents a useful and responsive PROM to evaluate HRQoL among those with acne in clinical trials and clinical practice. Future studies are needed to evaluate the interpretability of the measure (i.e. identifying severity strata and minimally important differences).